Skip to main content

Table 1 Characteristics of included studies

From: Efficacy and safety of IL-6 inhibitors in patients with COVID-19 pneumonia: a systematic review and meta-analysis of multicentre, randomized trials

First author Acronym Journal Setting Trial registration number Blinding Treatment Control
Gordon AC REMAP-CAP N Engl J Med COVID-19 critically ill patients ClinicalTrials.gov NCT02735707 Open-label Tocilizumab, sarilumab Standard care
Hermine O CORIMUNO-TOCI 1 JAMA Intern Med COVID-19 moderate/severe pneumonia ClinicalTrials.gov NCT04331808 Open-label Tocilizumab Standard care
Lescure FX N/A Lancet Respir Med COVID-19 severe pneumonia ClinicalTrials.gov NCT04327388 Double-blind Sarilumab Placebo
RECOVERY Collaborative Group RECOVERY Lancet COVID-19 pneumonia (SpO2 < 92%), elevated CRP ClinicalTrials.gov NCT04381936 Open-label Tocilizumab Standard care
Rosas IO COVACTA N Engl J Med COVID-19 severe pneumonia ClinicalTrials.gov NCT04320615 Double-blind Tocilizumab Placebo
Rutgers A PreToVid SSRN Electron J COVID-19 pneumonia with hyperinflammation Netherlands Trial Register NL8504 Open-label Tocilizumab Standard care
Salama C EMPACTA N Engl J Med COVID-19 pneumonia, not on NIMV/IMV ClinicalTrials.gov NCT04372186 Double-blind Tocilizumab Placebo
Salvarani C RCT-TCZ-COVID-19 JAMA Intern Med COVID-19 pneumonia, hyperinflammatory state, not on MV, not in ICU ClinicalTrials.gov NCT04346355 Open-label Tocilizumab Standard care
Sivapalasingam S N/A medXriv COVID-19 pneumonia requiring supplemental oxygen ClinicalTrials.gov NCT04315298 Double-blind Sarilumab Placebo
Soin AS COVINTOC Lancet Respir Med COVID-19 moderate-to-severe pneumonia Clinical Trials Registry India CTRI/2020/05/025369 Open-label Tocilizumab Standard care
Stone JH BACC Bay Tocilizumab Trial N Engl J Med COVID-19 pneumonia, hyperinflammatory state, not on MV ClinicalTrials.gov NCT04356937 Double-blind Tocilizumab Placebo
Talaschian M N/A Research Square COVID-19 pneumonia with elevated CRP/IL-6, not on IMV Iranian Registry of Clinical Trials IRCT20081027001411N4 Open-label Tocilizumab Standard care
Veiga VC TOCIBRAS BMJ COVID-19 severe/critical pneumonia ClinicalTrials.gov NCT04403685 Open-label Tocilizumab Standard care
Wang D N/A SSRN Electron J COVID-19 moderate/severe pneumonia, elevated IL-6 Chinese Clinical Trial Registry ChiCTR2000029765 Open-label Tocilizumab Standard care
Zhao H N/A Biomed Pharmacother COVID-19 pneumonia, elevated IL-6 ClinicalTrials.gov NCT04310228 Open-label Tocilizumab Favipiravir
  1. COVID-19: coronavirus disease 2019; CRP: C-reactive protein; IL-6: interleukin-6; IMV: invasive mechanical ventilation; MV: mechanical ventilation; N/A: not available; NIMV: non-invasive mechanical ventilation; SpO2: peripheral oxygen saturation